生物学的製剤の有効性と安全性: 体軸型脊椎関節炎に対する2022 ASAS/EULAR 推奨へのシステマティックレビュー

Ann Rheum Dis 2022; online ahead of print doi:10.1136/ard-2022-223298

New evidence supports the efficacy and safety of TNFi (originators/biosimilars) and IL-17i in r-axSpA and nr-axSpA. This systematic literature review was conducted to inform the taskforce of the 2022 update of the ASAS-EULAR recommendations.

Interestingly, IL-23i failed to show relevant effects. Observational studies are needed to confirm long-term IL-17i safety. This review informed the 2022 ASAS-EULAR management recommendations for axSpA, highlighting new evidence on efficacy and safety of existing and new bDMARDs

Keywords:


Publication thumbnail: 生物学的製剤の有効性と安全性: 体軸型脊椎関節炎に対する2022 ASAS/EULAR 推奨へのシステマティックレビュー
LinkedIn